CanSino Biologics Inc. (CASBF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 322.79 means the share price is 322.79 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $1.61B is the value of all shares combined. Beta 1.32: the stock has moved about 32% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCanSino Biologics Inc. (CASBF) trades at $4.60. CanSino Biologics Inc. is a China-based biopharmaceutical company specializing in the development, manufacturing, and commercialization of innovative vaccines. Market cap: $1.61B, Sector: Healthcare.
Price as of Sep 10, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for CASBF: CASBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CASBF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
CASBF: 1/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
CanSino Biologics Inc. (CASBF) Healthcare & Pipeline Overview
CanSino Biologics Inc. is a Chinese vaccine company focused on developing and commercializing innovative vaccines, including its COVID-19 vaccine, Convidecia, and vaccines for other infectious diseases like Ebola and meningitis, positioning itself within China's growing biopharmaceutical market amidst competition from both domestic and international players.
What Is the Investment Thesis for CASBF?
CanSino Biologics presents a mixed investment case. Its COVID-19 vaccine, Convidecia, provided significant revenue during the pandemic, but future growth hinges on its pipeline of other vaccines. The company's high P/E ratio of 322.79 suggests that investors have high expectations for future earnings growth. CanSino's success depends on navigating regulatory approvals in China, successfully commercializing its pipeline products, and maintaining a competitive edge in the vaccine market. The company's ongoing research and development efforts, particularly in pneumococcal and tuberculosis vaccines, represent potential growth catalysts. However, the company faces competition from established global vaccine manufacturers and domestic players.
Based on FMP financials and quantitative analysis
CASBF Key Highlights
Market capitalization of $1.61B indicates CanSino Biologics' current valuation in the market.
- A P/E ratio of 322.79 suggests that the company's stock price is high relative to its earnings.
- Gross margin of 100.0% reflects efficient vaccine production and sales.
- Profit margin of 2.6% indicates the percentage of revenue that turns into profit.
- Beta of 1.32 suggests the stock is more volatile than the market.
Who Are CASBF's Competitors?
CASBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| APNHY Aspen Pharmacare Holdings Limited | $9.73 | 0.00% | $4.32B | — |
| ARSUF Fagron N.V. | $27.50 | 0.00% | $2.02B | 549-signal |
| CHSYF China Medical System Holdings Limited | $1.57 | 0.00% | $3.80B | — |
| CURLF Curaleaf Holdings, Inc. | $9.83 | -4.10% | $2.60B | 539-signal |
| DMPHF Dermapharm Holding SE | $47.69 | 0.00% | $2.36B | — |
| ANIP ANI Pharmaceuticals, Inc. | $71.46 | +1.07% | $1.62B | 865-pillar |
| GTBIF Green Thumb Industries Inc. | $7.49 | -3.73% | $1.64B | 579-signal |
| PAHC Phibro Animal Health Corporation | $36.58 | -0.60% | $1.48B | 725-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are CASBF's Key Strengths?
Innovative vaccine technologies.
- Strong manufacturing capabilities.
- Established presence in the Chinese market.
- Successful development of COVID-19 vaccine.
What Are CASBF's Weaknesses?
High P/E ratio.
- Reliance on the Chinese market.
- Limited international presence.
- Dependence on regulatory approvals.
What Could Drive CASBF Stock Higher?
Regulatory approvals for new vaccine candidates in China.
- Expansion of manufacturing capacity to meet growing demand.
- Progress in clinical trials for pneumococcal and tuberculosis vaccines.
- Potential partnerships with international organizations for global distribution.
- Continued research and development of innovative vaccine technologies.
What Are the Key Risks for CASBF?
Negative return on equity (-0.0%) — the business is not currently generating profit on shareholder capital.
- Rich valuation — a P/E of 322.79 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
- Competition from established vaccine manufacturers.
- Regulatory challenges and delays in approvals.
- Fluctuations in demand for vaccines.
- Patent expirations and intellectual property disputes.
- Dependence on the Chinese market.
What Are the Growth Opportunities for CASBF?
- Expansion of Vaccine Portfolio: CanSino has an opportunity to expand its vaccine portfolio beyond COVID-19. The development and commercialization of vaccines for diseases like pneumococcal disease (PBPV and PCV13i) and tuberculosis (TB Booster) can drive future revenue growth. The global pneumococcal vaccine market is projected to reach $12.9 billion by 2027, while the TB vaccine market is expected to grow as well, driven by the need for more effective TB prevention strategies.
- International Market Expansion: While currently focused on the Chinese market, CanSino can explore opportunities to expand its reach internationally, particularly in developing countries with unmet needs for vaccines. This expansion could involve partnerships with local distributors or establishing manufacturing facilities in other regions.
- Development of Combination Vaccines: CanSino is developing combination vaccines like the DTcP-Hib Combo vaccine, which can provide protection against multiple diseases with a single injection. Combination vaccines can improve vaccination rates and reduce healthcare costs. The global market for combination vaccines is growing, driven by the convenience and cost-effectiveness of these products.
- Focus on Innovative Vaccine Technologies: CanSino's use of adenovirus vector technology for its COVID-19 vaccine demonstrates its commitment to innovation. The company can continue to invest in research and development of new vaccine technologies to improve vaccine efficacy, safety, and delivery. This includes exploring mRNA vaccine technology, which has shown promise in the development of COVID-19 vaccines.
- Partnerships and Collaborations: CanSino can leverage partnerships and collaborations with other pharmaceutical companies, research institutions, and government agencies to accelerate vaccine development and commercialization. These partnerships can provide access to new technologies, funding, and market expertise. Collaboration with international organizations like the WHO can also facilitate access to global markets.
What Are CASBF's Competitive Advantages?
- Proprietary vaccine technologies.
- Established manufacturing capabilities in China.
- Strong relationships with government agencies.
- First-mover advantage in certain vaccine markets in China.
What Does CASBF Do?
CanSino Biologics Inc., founded in 2009 and headquartered in Tianjin, China, is a biopharmaceutical company dedicated to developing, manufacturing, and commercializing vaccines. The company's initial focus was on developing vaccines for prevalent infectious diseases. A key milestone was the development of Ad5-EBOV, an Ebola virus vaccine. CanSino gained prominence during the COVID-19 pandemic with its development of Convidecia, a single-dose COVID-19 vaccine. The company also produces MCV2 and MCV4 vaccines for the prevention of N. meningitides. CanSino continues to expand its pipeline with vaccines in various stages of development, including DTcP vaccines for infants, Tdcp Adolescent and Adult vaccines, and PBPV, a serotype-independent protein-based pneumococcal vaccine. The company is also engaged in preclinical research for vaccines targeting diseases such as adenovirus, ZIKA virus, meningitis, shingles, and polio. CanSino's geographic focus is primarily within China, aligning with the country's national health priorities and market demands.
What Products and Services Does CASBF Offer?
- Develops vaccines for infectious diseases.
- Manufactures vaccines in China.
- Commercializes vaccines in the Chinese market.
- Focuses on vaccines for COVID-19, Ebola, and meningitis.
- Conducts clinical trials for new vaccine candidates.
- Engages in preclinical research for future vaccines.
How Does CASBF Make Money?
- Develops proprietary vaccine technologies.
- Manufactures vaccines in its own facilities.
- Sells vaccines to government agencies and healthcare providers in China.
- Generates revenue through vaccine sales.
What Industry Does CASBF Operate In?
CanSino Biologics operates in the global vaccine market, which is characterized by increasing demand due to emerging infectious diseases and growing awareness of preventative healthcare. The market is dominated by established players like Pfizer and GSK, but also includes emerging companies like CanSino focusing on specific regional markets. The Chinese vaccine market is driven by government initiatives to improve public health and increase vaccine accessibility. The industry is subject to stringent regulatory requirements and requires significant investment in research and development.
Who Are CASBF's Key Customers?
- Government agencies responsible for public health.
- Hospitals and clinics.
- Vaccination centers.
- Individuals seeking vaccination.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 63 |
| 2026-08-26 | 63 |
| 2026-08-29 | 63 |
| 2026-09-01 | 63 |
| 2026-09-04 | 63 |
| 2026-09-07 | 63 |
| 2026-09-10 | 63 |
What changed?
The score has stayed at 63.
Over the same 18 days the stock moved +17.9%.
CanSino Biologics Inc. Financial Trajectory
CanSino Biologics Inc. (CASBF) reported $358.1M in revenue for Jun 2026, reflecting 90.0% growth compared to the prior quarter. The company recorded net income of $39.5M, with diluted EPS of $0.16. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, CASBF averaged $0.04 in diluted EPS.
Company Profile
CanSino Biologics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tianjin, CN. The company is led by CEO Xue Feng Yu. CASBF has traded publicly since 2020.
How CanSino Biologics Inc. Is Valued
CanSino Biologics Inc. carries a market capitalization of $1.61B, placing it in the small-cap category.
Key Financial Metrics
Return on equity for CanSino Biologics Inc. stands at -0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.11 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
CanSino Biologics Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.43 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
CanSino Biologics Inc. has missed Wall Street's EPS estimate in 4 of its last 7 reported quarters — a mixed record worth weighing. Reported results have landed about 155.9% below estimates on average.
Forward Outlook
Wall Street analysts project CanSino Biologics Inc. revenue of about $1.45B for fiscal 2026, with EPS near $0.34. The estimate reflects 3 contributing analysts.
CASBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative vaccine technologies.
- Strong manufacturing capabilities.
- Established presence in the Chinese market.
- Successful development of COVID-19 vaccine.
Bear Case
- High P/E ratio.
- Reliance on the Chinese market.
- Limited international presence.
- Dependence on regulatory approvals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Jun 2026 | CN¥358M | CN¥40M | CN¥0.16 |
| Mar 2026 | CN¥188M | -CN¥40M | -CN¥0.16 |
| Dec 2025 | CN¥370M | CN¥13M | CN¥0.05 |
| Sep 2025 | CN¥310M | CN¥28M | CN¥0.11 |
Based on FMP financials and quantitative analysis · Reported in CNY
CASBF Latest News
No recent news available for CASBF.
CASBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CASBF.
Price Targets
Wall Street price target analysis for CASBF.
CASBF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CASBF; grades run from A+ (80-100) to F (below 30).
Leadership: Xuefeng Yu
CEO
Xuefeng Yu is the CEO of CanSino Biologics Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on vaccine development and commercialization. He has been instrumental in guiding CanSino through its growth phase, overseeing the development of key vaccine candidates and establishing partnerships with research institutions and government agencies. His leadership is focused on driving innovation and expanding CanSino's presence in the global vaccine market.
Track Record: Under Xuefeng Yu's leadership, CanSino Biologics has achieved significant milestones, including the development and approval of Convidecia, its COVID-19 vaccine. He has also overseen the expansion of CanSino's vaccine pipeline and the establishment of manufacturing facilities. His strategic decisions have positioned CanSino as a key player in the Chinese vaccine market.
CASBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CanSino Biologics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB, or that it may be unwilling or unable to meet those standards. Companies on this tier may have limited financial disclosure, which increases the risk for investors. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, leading to less transparency.
- OTC Tier: OTC Other
- Limited Financial Disclosure: The lack of transparency regarding CanSino Biologics' financial reporting makes it difficult for investors to assess the company's financial health and performance.
- Low Liquidity: The low trading volume associated with OTC Other stocks can make it challenging to buy or sell shares at desired prices.
- Regulatory Uncertainty: OTC Other companies are subject to fewer regulatory requirements than companies listed on major exchanges, which can increase the risk of fraud or mismanagement.
- Price Volatility: The limited liquidity and lack of information can lead to increased price volatility.
- Going Concern Risk: Companies on the OTC Other tier may face a higher risk of financial distress or bankruptcy.
- Verify the company's registration and legal status.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and their track record.
- Check for any regulatory actions or legal proceedings against the company.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established vaccine development and manufacturing operations.
- Development and approval of COVID-19 vaccine.
- Partnerships with research institutions and government agencies.
- Focus on addressing public health needs in China.
What Investors Ask About CanSino Biologics Inc. (CASBF) — Healthcare
Is CASBF a good stock?
Stock Expert AI does not rate CASBF buy, sell or hold. CanSino Biologics Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about CASBF stock?
Analyst coverage of CASBF stock is limited due to its OTC listing and focus on the Chinese market. However, key valuation metrics to consider include the company's high P/E ratio, which reflects investor expectations for future growth.
What are the key factors to evaluate for CASBF?
Evaluate CASBF on fundamentals, analyst consensus, and risk factors. P/E: 322.79x vs the S&P 500's ~20-25x. CanSino Biologics presents a mixed investment case. Not financial advice.
How frequently does CASBF data refresh on this page?
CASBF's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CASBF's recent stock price performance?
CanSino Biologics Inc. (CASBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative vaccine technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CASBF overvalued or undervalued right now?
CanSino Biologics Inc. (CASBF) trades at 322.79x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CASBF?
Yes, most major brokerages offer fractional shares of CanSino Biologics Inc. (CASBF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CASBF's earnings and financial reports?
CanSino Biologics Inc. (CASBF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for CASBF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.